Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam

J Clin Microbiol. 2006 Jul;44(7):2333-7. doi: 10.1128/JCM.00330-06.

Abstract

Vietnam is ranked 13th among the WHO list of 22 high-burden countries, based upon estimated total number of tuberculosis cases. Despite having a model national tuberculosis program, consistently achieving and exceeding WHO targets for detection and cure, drug-resistant and multidrug-resistant tuberculosis cases continue to rise. Rapid multidrug-resistant tests applicable in this setting, coupled with effective treatment regimens, would be a useful tool in reversing this trend, allowing early identification of patients with multidrug-resistant tuberculosis and avoiding resistance-amplifying regimens. Sequencing of consecutive isolates identified by the National Tuberculosis Program showed 89% of isoniazid-resistant isolates could be detected by targeting just 2 codons, katG 315 and -15C-->T in the inhA promoter, while rifampin resistance will be more complex to detect, with many different mutation and insertion events in rpoB. The most prevalent rifampin resistance-conferring mutations, as in other countries, were in rpoB codons 531 (43%), 526 (31%), and 516 (15%). However, a hybridization-based resistance test with probes targeting the 5 most common mutations would only detect 78% of rifampin-resistant isolates. Overall, these data suggest that rifampin resistance may be used as a surrogate marker for multidrug-resistant tuberculosis and that a sensitivity of between 70 to 80% may be possible for rapid molecular detection of multidrug-resistant tuberculosis in this setting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Antitubercular Agents / pharmacology*
  • Bacterial Proteins / genetics
  • Catalase / genetics
  • DNA, Bacterial / chemistry
  • DNA, Bacterial / genetics
  • DNA-Directed RNA Polymerases
  • Drug Resistance, Bacterial / genetics*
  • Hospitals
  • Humans
  • Isoniazid / pharmacology*
  • Mutation
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / isolation & purification
  • Promoter Regions, Genetic
  • Recombination, Genetic
  • Rifampin / pharmacology*
  • Sequence Analysis, DNA
  • Tuberculosis / microbiology*
  • Vietnam

Substances

  • Antitubercular Agents
  • Bacterial Proteins
  • DNA, Bacterial
  • rpoB protein, Mycobacterium tuberculosis
  • Catalase
  • katG protein, Mycobacterium tuberculosis
  • DNA-Directed RNA Polymerases
  • Isoniazid
  • Rifampin